OPT 302

Drug Profile

OPT 302

Alternative Names: OPT-302; soluble VEGFR-3; VGX 300

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vegenics
  • Developer Opthea
  • Class Eye disorder therapies
  • Mechanism of Action Vascular endothelial growth factor C inhibitors; Vascular endothelial growth factor D inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Wet age-related macular degeneration

Most Recent Events

  • 15 Aug 2017 Updated efficacy data from a phase I/II trial in Wet age related macular degeneration released by Opthea
  • 09 Aug 2017 Opthea completes a phase I/II trial in Wet age-related macular degeneration in USA (Intravitreous)
  • 09 Aug 2017 Opthea plans a phase IIb trial for Wet age-related macular degeneration (Treatment-naive) in USA, United Kingdom and European Union (Intravitreous, Injection) in the second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top